Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Non-Current Deferred Tax Liability (2019 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Non-Current Deferred Tax Liability for 13 consecutive years, with $86.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability rose 17.74% to $86.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.1 million through Dec 2025, up 17.74% year-over-year, with the annual reading at $86.1 million for FY2025, 17.74% up from the prior year.
  • Non-Current Deferred Tax Liability hit $86.1 million in Q4 2025 for Ligand Pharmaceuticals, up from $22.7 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $86.1 million in Q4 2025 to a low of $22.7 million in Q3 2025.
  • Historically, Non-Current Deferred Tax Liability has averaged $42.3 million across 5 years, with a median of $32.4 million in 2023.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: skyrocketed 366.58% in 2021 and later plummeted 52.67% in 2022.
  • Year by year, Non-Current Deferred Tax Liability stood at $30.9 million in 2021, then decreased by 0.78% to $30.6 million in 2022, then grew by 3.29% to $31.6 million in 2023, then skyrocketed by 131.3% to $73.1 million in 2024, then increased by 17.74% to $86.1 million in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for LGNDZ at $86.1 million in Q4 2025, $22.7 million in Q3 2025, and $32.2 million in Q2 2025.